Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

15 enrolled

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05827614 2026-01-23

POTENTIATE

Phase 1 Active not recruiting

85 enrolled

BreastHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

43 enrolled 15 charts

Genitourinary

Advanced and Metastatic Urothelial Cancer

NCT05727176 2025-12-29

FOENIX-CCA4

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Phase 2 Recruiting

24 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03784014 2025-12-11

MULTISARC

Phase 3 Active not recruiting

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT04828486 2025-11-18

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast

Breast Neoplasms

NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Phase 2 Terminated

115 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT05036681 2025-09-17

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 8 charts

Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

917 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT04965818 2024-09-19

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Phase 1 Terminated

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03767075 2024-04-25

BoB

Phase 2 Recruiting

1,000 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

TAPUR

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

POTENTIATE

ESMART

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

FOENIX-CCA4

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

MULTISARC

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Futibatinib in Patients With Specific FGFR Aberrations

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

SAFIR-ABC10

AB122 Platform Study

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

BoB